A comprehensive review highlights the complex and tissue-specific influence of the FTO gene on metabolism, obesity, and insulin resistance, calling for cautious interpretation of its role in disease pathways.
A detailed review in Dove Press argues that the fat mass and obesity-associated gene, better known as FTO, sits at the centre of a complex metabolic story that spans obesity, insulin resistance and type 2 diabetes. But the paper also stresses a crucial caveat: the biology behind FTO is not straightforward, because signals from the FTO gene locus do not always mean the FTO protein itself is driving disease. In some cases, the DNA region appears to affect neighbouring genes instead, most notably IRX3 and RPGRIP1L, which complicates attempts to pin down a single pathway linking FTO to metabolic illness.
The review traces how FTO first rose to prominence after genome-wide association studies identified it as the first obesity susceptibility gene. Since then, variants in the FTO region have repeatedly been linked with higher body mass index and greater obesity risk, although the size of that effect differs across populations. The authors note that the association between FTO variants and type 2 diabetes weakens markedly once body weight is taken into account, supporting the view that much of the diabetes risk may be mediated through adiposity rather than through a direct effect on glucose metabolism.
At the protein level, FTO is described as an iron- and 2-oxoglutarate-dependent enzyme that acts as an RNA demethylase, removing methyl marks from RNA molecules and thereby influencing how transcripts are processed, stabilised and translated. The review highlights continuing debate over which RNA marks matter most in living tissue, especially internal m6A sites versus cap-adjacent m6Am. It also makes clear that FTO is not confined to one compartment or one tissue: it is found in the nucleus and cytoplasm, is expressed in the brain, muscle, endocrine organs and pancreas, and may even appear in circulating blood or exosomes under some conditions.
Much of the paper focuses on the ways FTO may shape metabolism in specific organs. In the liver, increased FTO expression is linked with higher glucose production and stronger expression of genes involved in gluconeogenesis, the process by which the body makes new glucose. The review says FTO also appears to encourage fat production in the liver while limiting fatty acid breakdown, a combination that can contribute to steatosis and, over time, steatohepatitis. In adipose tissue, FTO is described as a promoter of adipocyte development, in part by altering alternative splicing of RUNX1T1 and by reinforcing transcriptional programmes driven by C/EBP-β, PPARγ and other adipogenic factors.
The hypothalamus receives similar attention, particularly because of its role in appetite regulation and leptin signalling. The review says FTO interacts with the leptin pathway directly and indirectly, including through effects on STAT3 signalling and through the regulation of ciliary trafficking machinery that helps leptin receptors reach the correct cellular location. These mechanisms may help explain why obesity-associated variants in the FTO locus have been tied to disordered energy balance and leptin resistance. In skeletal muscle, meanwhile, the paper points to evidence that FTO affects mitochondrial function, oxidative metabolism and lipid storage, all of which are relevant to insulin sensitivity.
The most uncertain part of the story concerns pancreatic beta cells and insulin secretion. The review says experimental findings are mixed: some studies suggest that reducing FTO impairs insulin secretion and beta-cell survival, while others report little change in insulin output after FTO manipulation. The authors argue that these inconsistencies may reflect differences in cell models, species, duration of intervention and the distinct RNA pathways FTO can influence. Their broader conclusion is cautious but clear: although FTO is an important metabolic regulator, current evidence does not establish it as a validated clinical biomarker or a proven direct cause of type 2 diabetes. Instead, the paper frames FTO as a gene and protein with tissue-specific effects that remain scientifically important but not yet fully resolved.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
